^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    trastuzumab rezetecan (SHR-A1811)

    i
    Other names: SHR-A1811, SHRA1811, SHR A1811, SHR-1811, SHR1811, SHR 1811
    Company:
    Glenmark, Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    9d
    Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    trastuzumab rezetecan (SHR-A1811)
    17d
    A Multicenter, Open-Label, Randomized, Phase II Clinical Trial of Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer (ChiCTR2600120221)
    P2, N=108, ChongQing university cancer hospital; ChongQing university cancer hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Focus V (anlotinib) • capecitabine • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
    18d
    A Prospective, Multicenter, Single-Arm Clinical Study of Atezolizumab Combined with SHR-A1811and Pertuzumab in the Neoadjuvant Treatment of HER2-Positive Breast Cancer (ChiCTR2600118900)
    P2, N=50, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    18d
    Efficacy and safety of SHR-1811-based combination regimens in advanced HER2-overexpressing urothelial carcinoma: a single-center, multi-cohort, Exploratory research (ChiCTR2600118801)
    P=N/A, N=45, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    trastuzumab rezetecan (SHR-A1811)
    20d
    SHR-A1811-II-203: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=324, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Nov 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    26d
    Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    1m
    Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC (clinicaltrials.gov)
    P=N/A, N=1000, Not yet recruiting, Nanjing Tianyinshan Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    trastuzumab rezetecan (SHR-A1811)
    1m
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Fudan University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 overexpression • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    1m
    FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fudan University
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    everolimus • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
    1m
    REIN: Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov)
    P2, N=150, Recruiting, Henan Cancer Hospital | Trial completion date: Apr 2026 --> Jun 2029 | Trial primary completion date: Oct 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Avastin (bevacizumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
    1m
    A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • trastuzumab rezetecan (SHR-A1811)
    2ms
    SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    trastuzumab rezetecan (SHR-A1811) • Yidafan (ivonescimab)